2 months ago

Eli Lilly's Retatrutide Clears Heart Risk Hurdle

Eli Lilly's Retatrutide Clears Heart Risk Hurdle
Eli Lilly’s next-generation weight-loss shot clears another hurdle · livemint.com

Eli Lilly, a big pharmaceutical company, has a new weight-loss drug called retatrutide.

They did a study to check if it's safe for the heart, and it looks good.

This drug is special because it combines three different gut hormones, which makes it more effective than other weight-loss drugs.

Lilly wants to sell it as a biologic medicine, which would give them more protection and time before the government cuts prices.

They are waiting to ask the FDA for approval until early next year.

Some people are even trying to get black-market versions of the drug because it's so promising.

Key facts

Company
Eli Lilly & Co.
Drug Name
Retatrutide
Approval Pathway
Biologics License Application (BLA)
Expected FDA Filing
Early 2027
Potential Sales by 2036
$16 billion
Current Market Leader
Zepbound
Competitor
Novo Nordisk A/S

Quotes

Daniel Skovronsky

Chief Scientific and Product Officer of Eli Lilly

“"If approved, retatrutide would be a first: the first triple agonist, a medicine that acts on three pathways at once,"”
livemint.com

Sources

Related news